Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
CYP2S1 CRISPR/Cas9 KO Plasmid (h): sc-405785
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- CYP2S1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the CYP2S1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: CYP2S1 Antibody (G-1): sc-365806
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
CYP2S1 CRISPR/Cas9 KO Plasmid (h) | sc-405785 | 20 µg | $397.00 |
Overview
CYP2S1 encodes cytochrome P450 2S1, an extrahepatic monooxygenase that catalyzes oxidative metabolism of endogenous lipids and xenobiotic substrates. It has been linked to arachidonic acid and eicosanoid signaling, including oxygenation of fatty acid–derived mediators that can influence inflammatory and stress-response programs. CYP2S1 expression is enriched in epithelial tissues and is regulated by environmental and oxidative cues, supporting roles in barrier biology and chemical defense. Dysregulated CYP2S1 activity or expression has been associated with altered xenobiotic handling and redox balance in contexts such as inflammation and cancer biology, making it relevant for mechanistic studies of metabolism-driven phenotypes.
CYP2S1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the CYP2S1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the CYP2S1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the CYP2S1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish CYP2S1 protein expression.
This CRISPR knockout system enables efficient generation of CYP2S1-deficient cell models for investigation of CYP2S1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting CYP2S1 exon(s) critical for CYP2S1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple CYP2S1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by CYP2S1 CRISPR/Cas9 KO Plasmid (h) and CYP2S1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the CYP2S1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by CYP2S1 HDR Plasmid (h) and CYP2S1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by CYP2S1 homology arms to support homology-directed repair at defined CYP2S1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.